Leukemia Posts on Medivizor
Navigation Menu

Leukemia Posts on Medivizor

Stem cell transplantation in chronic myeloid leukemia

Posted by on Apr 9, 2017 in Leukemia | 0 comments

In a nutshell This review discussed the role of stem cell transplantation in patients with chronic myeloid leukemia. Some background Stem cell (immature blood cell) transplantation (SCT) has had a long history in the treatment of chronic myeloid leukemia (CML). Patients who have a matched donor (someone who is a close genetic match, such as a...

Read More

Stem cell transplantation: Minimal residual disease response as a predictors of success

Posted by on Apr 9, 2017 in Leukemia | 0 comments

In a nutshell This study examined the role of stem cell transplantation in adult acute lymphoblastic leukemia (ALL) patients treated with pediatric-inspired chemotherapy. The study also explored whether minimal residual disease could help to predict which patients would benefit from stem cell transplant. Researchers reported that early minimal residual...

Read More

Current treatment practices for childhood ALL

Posted by on Apr 9, 2017 in Leukemia | 0 comments

In a nutshell This study examined evidence on treatment practices for childhood acute lymphoblastic leukemia (ALL). Some background ALL is a type of cancer in which the bone marrow makes too many lymphoblasts (a type of immature white blood cell). It is the most common type of childhood cancer. Advances in risk classification, supportive care, and...

Read More

Unrelated umbilical cord blood as a valid alternative source for stem cell transplantation

Posted by on Apr 9, 2017 in Leukemia | 0 comments

In a nutshell This study examined different sources of allogenic (donor) stem cell transplantation for adult acute lymphoblastic leukemia (ALL) patients who are in first or second remission. Researchers reported no significant differences in survival across allogenic stem cell sources. In the absence of a matched related or unrelated adult donor,...

Read More

Not just useful in treatment selection: Minimal residual disease levels after remission can predict long-term outcomes

Posted by on Apr 9, 2017 in Leukemia | 0 comments

In a nutshell This study examined the effect of minimal residual disease (MRD) levels at various time points on clinical outcomes in children with acute lymphoblastic leukemia (ALL). Researchers concluded that MRD levels during and after remission can predict ALL outcomes. Some background ALL is a type of cancer in which the bone marrow makes too...

Read More

Is reduced-intensity conditioning an effective alternative to myeloablative therapy before stem cell transplantation?

Posted by on Apr 9, 2017 in Leukemia | 0 comments

In a nutshell The aim of this study was to compare conventional myeloablative therapy and reduced-intensity conditioning (RIC) before stem cell transplantation in patients with adult acute lymphoblastic leukemia (ALL). Researchers concluded that RIC is a suitable alternative for patients who may not tolerate myeloablative therapy. Some background...

Read More

Dasatinib in early chronic-phase chronic myeloid leukemia

Posted by on Apr 9, 2017 in Leukemia | 0 comments

In a nutshell The current study explored the use of dasatinib as an initial treatment for early chronic phase chronic myeloid leukemia (CML). The authors concluded that dasatinib was a safe and effective first-line treatment. Some background The standard first-line treatment for CML is imatinib (Gleevac). Imatinib is a tyrosine kinase inhibitor...

Read More

Dasatinib in early chronic-phase chronic myeloid leukemia

Posted by on Apr 9, 2017 in Leukemia | 0 comments

In a nutshell The current study explored the use of dasatinib as an initial treatment for early chronic phase chronic myeloid leukemia (CML). The authors concluded that dasatinib was a safe and effective first-line treatment. Some background The standard first-line treatment for CML is imatinib (Gleevac). Imatinib is a tyrosine kinase inhibitor...

Read More

What is the optimal dose of imatinib in newly diagnosed chronic myeloid leukemia?

Posted by on Apr 9, 2017 in Leukemia | 0 comments

In a nutshell This study explored whether a higher starting dose of imatinib (Gleevac) is safe and effective as a first-line treatment for chronic myeloid leukemia (CML). This study concluded that response rates were similar between the higher and lower dose after 1 year, but the response occurred earlier with the higher dose. Some background...

Read More